MEASLES, MUMPS, RUBELLA (MMR) VACCINE
VACCINATION SCHEDULE: Two doses of MMR at least 28 days apart after 12 months of age.
MAJOR INDICATIONS:
• All college students born after 1956 without lab evidence of disease.
• All health care professional students without other evidence of immunity should receive two doses of MMR.
• Those born before 1957 without other evidence of immunity should receive one dose if not in an outbreak setting and two doses if in an outbreak.
CONTRAINDICATIONS AND PRECAUTIONS:
Pregnancy, history of hyper-sensitivity or anaphylaxis to any of the components in the vaccine. Receipt of blood products and moderate or severe acute infections. Guidelines exist for vaccination of persons with altered immunocompetence.
MENINGOCOCCAL QUADRIVALENT (A, C, Y, W-135) VACCINE
• Conjugate (Preferred)
• Polysaccharide (Acceptable alternative if conjugate not available)
VACCINATION SCHEDULE:
• Initial dose of conjugate vaccine: 11-12 yrs of age • Booster dose: 16 yrs of age • If initial dose given age 13-15 yrs: booster dose at 16-18 yrs of age • If initial dose given age ≥16 yrs, no booster dose required
Persons with persistent complement component deficiencies or asplenia should receive a 2-dose primary series administered 2 months apart and then receive a booster dose every 5 years. Adolescents aged 11 through 18 years with HIV infection should be routinely vaccinated with a 2-dose primary series. Other persons with HIV who are vaccinated should receive a 2-dose primary series administered 2 months apart. All other persons at increased risk for meningococcal disease (e.g., microbiologists or travelers to an epidemic or highly endemic country) should receive a single primary dose.
For colleges and university with meningococcal vaccine policies as a requirement of enrollment or on-campus living: students 21 years of age and younger should have documentation of a dose of conjugate vaccine at ≥16 years of age. The booster dose can be administered any time after the 16th birthday. The minimum interval between doses of meningococcal conjugate vaccine is 8 weeks.
Routine vaccination of healthy persons who are not at increased risk for exposure is not recommended after age 21 years.
MAJOR INDICATIONS:
Adolescents 11-18 years of age and other populations at increased risk, including college students living in residence halls/similar housing, etc., persons with persistent complement deficiencies or asplenia, laboratory personnel with exposure to aerosolized meningococci, and travelers to hyperendemic or endemic areas of the world. Non-freshmen college students may choose to be vaccinated to reduce their risk of meningococcal disease. *
CONTRAINDICATIONS AND PRECAUTIONS:
History of hypersensitivity or serious adverse reaction to any of the components in the vaccine.
Avoid vaccinating persons who are known to have experienced Guillain-Barre (GBS) syndrome.
There is a theoretical risk of increased rates of local or systemic reactions when two diphtheria toxoid -containing vaccines are administered within a short interval (i.e., on different days 
• Defer in pregnant or lactating females unless at increased risk.
• History of hypersensitivity to any of the components of the vaccine.
• MenB-4 (Bexsero ®) : use with caution if hypersensitive to latex.
• The two vaccines are not interchangeable, so the same product must be used for all doses.
TETANUS, DIPHTHERIA, PERTUSSIS VACCINE
• DT: pediatric (<age 7 years) preparation of diphtheria and tetanus toxoids.
• DTaP: pediatric (<age 7 years) preparation of diphtheria, tetanus toxoids, and acellular pertussis.
• DTP (also known as DTwP): pediatric (<age 7 years) preparation of diphtheria, tetanus toxoids, and whole cell pertussis (no longer available in the U.S.).
• Td: 7 years and older preparation of tetanus toxoid and reduced diphtheria toxoid.
• Tdap: adolescent and older preparation of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis.
VACCINATION SCHEDULE:
Primary series in childhood (4 doses: DT, DTaP, DTP, or Td)
Booster doses: For adolescents 11-18 and adults 19-64: single dose of Tdap. Tdap can be administered regardless of interval since the last tetanus or diphtheria toxoid-containing vaccine.
Routine booster dose intervals:
Adults should receive Td boosters at 10 year intervals, beginning 10 years after receiving Tdap.
Tetanus prophylaxis in wound management: For all age groups, patients who require a tetanus toxoid containing vaccine as part of wound management should receive Tdap instead of Td if they have not previously received Tdap. If Tdap is not available or was administ ered previously, Td should be administered.
MAJOR INDICATIONS:
All college students. One dose of Tdap for all individuals ages 11-64 regardless of interval since last Td booster.
CONTRAINDICATIONS AND PRECAUTIONS:
There is a theoretical risk of increased rates of local or systemic reactions when two diphtheria toxoid -containing vaccines are administered within a short interval (i.e., on different days). Efforts should be made to administer Tdap and tetravalent meningococcal conjugate (MCV4) vaccines simultaneously if both are indicated. If simultaneous vaccination is not feasible, Tdap and MCV4 vaccines (which contain d iphtheria toxoid) can be administered in any sequence.
VARICELLA VACCINE VACCINATION SCHEDULE:
Two doses of varicella-containing vaccine at least 12 weeks apart if vaccinated between 1 and 12 years of age and at least 4 weeks apart if vaccinated at age 13 years or older.
MAJOR INDICATIONS:
• All college students without other evidence of immunity (e.g., born in the U.S. before 1980, a history of disease, two prior doses of varicella vaccine, or a positive antibody).
• All health care professional students with only one documented dose of vaccine or with a negative antibody titer should receive a total of two doses of vaccine.
CONTRAINDICATIONS AND PRECAUTIONS:
Pregnancy, history of hyper-sensitivity or anaphylaxis to any of the components in the vaccine, and severe illness. Guidelines exist for vaccination of persons with altered immunocompetence.
OTHER VACCINES RECOMMENDED FOR ADULTS
The following vaccines are recommended for adults. College matriculation provides the opportunity to assure that students receive the appropriate vaccines.
HEPATITIS A VACCINE
VACCINATION SCHEDULE: Given as a series of 2 doses (given at 0, 6-12 mo.) for age 12 months or greater. *
MAJOR INDICATIONS:
Recommended for routine use in all adolescents through the age of 18 and in particular for adolescent and adult high-risk groups (i.e., persons traveling to countries where hepatitis A is moderately or highly endemic, men who have sex with men, users of injectable and non-injectable drugs, persons who have clotting-factor disorders, persons working with nonhuman primates, and persons with chronic liver disease).
CONTRAINDICATIONS AND PRECAUTIONS:
History of hypersensitivity to any of the components of the vaccine. *Combined hepatitis A and B vaccines may be given as a series of 3 doses (given at 0, 1-2, and 6-12 mo.) for 18 years of age and older.
HEPATITIS B VACCINE VACCINATION SCHEDULE:
Given as a series of 3 age appropriate doses (given at 0, 1-2 mo., and 6-12 mo.) at any age. Adolescents ages 11-15 years can be given 2 adult doses (given at 0 and 4-6 mo.) *
MAJOR INDICATIONS:
All college students. In particular, students enrolled in health care professional programs should receive Hepatitis B vaccination.
CONTRAINDICATIONS AND PRECAUTIONS:
History of hypersensitivity to any of the components of the vaccine. (given at 0, 1 -2, and 6-12 mo.) for 18 years of age and older.
*Combined hepatitis A and B vaccines may be given as a series of 3 doses

HUMAN PAPILLOMAVIRUS (HPV) VACCINE
• 9-valent (HPV9) [Bivalent (HPV2) and Quadrivalent (HPV4) are no longer available]
VACCINATION SCHEDULE:
The 9-valent vaccine may be used to complete the series begun with a different product.
All persons 11-14 years: 2 doses separated by at least 6 months; may start at age 9 for increased risk groups 
MAJOR INDICATIONS:
All 11-or 12-year olds; may be started at age 9.
If not vaccinated previously: women through age 26 and men through age 21.
If not vaccinated previously:
• Young men through age 26 who have sex with men, including those who identify as gay or bisexual or who intend to have sex with men;
• Young adults through age 26 who are transgender or gender non-conforming; and • Young adults through age 26 with certain immunocompromising conditions (including HIV).
The HPV vaccines are indicated for prevention of cervical cancers in women and for use in both females and males for the prevention of pre-cancers and genital warts, anal cancer, and anal intraepithelial dysplasia caused by HPV types included in the vaccine. No HPV or Pap test screening is required prior to administering vaccine; routine cervical cancer screening should continue according to current recommendations.
CONTRAINDICATIONS AND PRECAUTIONS:
Pregnancy, history of hyper-sensitivity to yeast or to any vaccine component; moderate or severe acute illnesses (defer vaccine until improved); may be given to immunocompromised males and females but vaccine responsiveness and efficacy may be reduced. 
PNEUMOCOCCAL VACCINE
POLIO VACCINE • Inactivated (IPV)
• Oral poliovirus (OPV no longer available in U.S.)
VACCINATION SCHEDULE: Primary series in childhood with IPV alone, OPV alone, or IPV/OPV sequentially; IPV booster only if needed for travel after age 18 years.
MAJOR INDICATIONS:
IPV for certain international travelers to areas or countries where polio is epidemic or endemic.
CONTRAINDICATIONS AND PRECAUTIONS:
History of hypersensitivity to any of the components of the vaccine. 
PART II: TO BE COMPLETED AND SIGNED BY YOUR HEALTH CARE PROVIDER.
All information must be in English. Measles/Mumps/Rubella (MMR): 2 doses of MMR vaccine at least 28 days apart after 12 months of age OR 2 doses of measles and 2 doses of Mumps at least 28 days apart after 12 months of age and one dose of rubella after 12 months of age OR laboratory proof of immunity to measles/mumps/rubella.
A. MMR (MEASLES, MUMPS
Tetanus/Diphtheria/Pertussis: In addition to primary series, all Health Care Personnel (HCP) should receive 1 dose of Tdap and have documentation of a Td or Tdap within the past 10 years.
Tuberculosis Testing: The CDC recommends initial base line testing with a 2-step TB skin test or a blood test for TB infection. Subsequent annual or serial screening is determined by state regulations or risk assessment.
Varicella: 2 doses of varicella vaccine given at least 4 weeks apart OR laboratory proof of immunity for those with a history of disease. If titer is negative or equivocal, give 2-dose varicella vaccine series. Do not repeat titer after series completion.
Note: Local requirements and clinical circumstances should be taken into consideration when using these guidelines to develop an in stitutional immunization policy for health science students.
Hepatitis B:
Students must have a series of 3 hepatitis B vaccines AND a positive (≥10 mIU/mL) serological quantitative Hepatitis B surface antibody titer (anti-HBs or HBsAb) that was performed at least 1-2 months after the 3 rd dose of hepatitis B vaccine. A positive titer without documentation of the 3 shot series will not be accepted.
For students with remote history of documented vaccine series completion without titer:
Draw anti-HBs titer upon matriculation
• If the anti-HBs titer is negative or equivocal, administer 1 dose of hepatitis B vaccine (#4) and re-titer at least 1-2 months after the dose.
• If the second anti-HBs titer is negative, the student will get 2 additional hepatitis B vaccines (#5 and #6) at 1 month and 6 months following dose #4. Students should pay particular attention to the date ranges in between the 3 hepatitis B vaccine doses to ensure that they are given at the appropriate time intervals for compliance.
• A final anti-HBs titer should be performed 1-2 months after the 3 rd vaccine (dose #6) in the repeated hepatitis B series.
• If the student has received 2 complete series of hepatitis B vaccine (6 doses total) and does not have a positive anti -HBs titer, they are considered a "non-responder" and must be evaluated by student health personnel for further evaluation and recommendations.
• HCP who are non-responders should be considered susceptible to hepatitis B infection and should be counseled about precautions to prevent HBV infection and the need to receive hepatitis B Immunoglobulin upon exposure to hepatitis B surface antigen positive (HBsAg) blood or fluids or blood or fluids with unknown HBsAg status. Non-responders should also be tested for HBsAg to evaluate for chronic hepatitis B infection. HCP who are chronic hepatitis B carriers should be counseled as to local and state guidelines for the safe provision of healthcare.
For unvaccinated HCP students or those with recent history of documented vaccine completion
Administer a 3-dose series of hepatitis B vaccine at 0, 1, and 6 months AND perform anti-HBs titer 1-2 months after dose #3 to document immunity.
• If anti-HBs is greater than or equal to 10 mIU/ml, the HCP is considered immune and no further testing or vaccination is recommended
• If the anti-HBs titer is less than 10 mIU/ml, the student should receive 3 additional doses of vaccine per the usual schedule of 0, 1, and 6 months, and a repeated titer should be performed 1-2 months after dose #3.
Influenza:
It is strongly recommended that all healthcare personnel receive the influenza vaccine yearly and many clinical sites require it as a condition of rotation for students.
